Relapse Prevention Group Programme for service users with an international statistical classification of diseases and related health problems (ICD10, chapter F20) diagnosis of schizophrenia in a community setting - a randomised controlled trial
ISRCTN | ISRCTN11138647 |
---|---|
DOI | https://doi.org/10.1186/ISRCTN11138647 |
Secondary identifying numbers | JUMRC6002 |
- Submission date
- 29/06/2006
- Registration date
- 27/07/2006
- Last edited
- 04/02/2010
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Mental and Behavioural Disorders
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Plain English summary of protocol
Not provided at time of registration
Contact information
Mr Rami Jumnoodoo
Scientific
Scientific
Park Royal Centre for Mental Health
Acton Lane
Central Way
London
NW10 7NS
United Kingdom
Phone | +44 (0)20 8955 4444 |
---|---|
rami.jumnoodoo@nhs.net |
Study information
Study design | Randomised controlled trial |
---|---|
Primary study design | Interventional |
Secondary study design | Randomised controlled trial |
Study setting(s) | Not specified |
Study type | Treatment |
Scientific title | |
Study acronym | RPGP |
Study objectives | Following an eight week Relapse Prevention (RP) programme, service users have: 1. Decrease in admission rates 2. Decrease in length of stay following admission 3. Increase in the attendance rates of hospital appointments 4. Increased their self-efficacy 5. Greater knowledge in medication, support services and illnesses 6. Improved quality of life 7. Reduced severity of symptomatology It is expected that there will be a significant difference in these variables between individuals receiving the RP programme (treatment group) and individuals receiving treatment as usual (comparison group) that this is maintained at three and six months follow-up. |
Ethics approval(s) | COREC - Brent Medical Ethics Committee |
Health condition(s) or problem(s) studied | Schizophrenia |
Intervention | Relapse prevention programme as opposed to treatment as usual |
Intervention type | Other |
Primary outcome measure | 1. Increased self-efficacy 2. Greater knowledge in medication, support services and illnesses 3. Improved quality of life 4. Reduced severity of symptomatology |
Secondary outcome measures | 1. Decrease in admission rates 2. Decrease in length of stay following admission 3. Increase in the attendance rates of hospital appointments |
Overall study start date | 11/09/2006 |
Completion date | 11/05/2007 |
Eligibility
Participant type(s) | Patient |
---|---|
Age group | Adult |
Lower age limit | 18 Years |
Upper age limit | 45 Years |
Sex | Both |
Target number of participants | 96 |
Key inclusion criteria | 1. Newly diagnosed by a Community Psychiatric Nurse (CPN) 2. Age group 18-45, men and women 3. Have a diagnosis of schizophrenia (ICD 10-F20) 4. Sufficiently stable to take part in the programme 5. Assessment conducted by CPN 6. Living in the community 7. Be able to consent to participate 8. Be on a therapeutic dose of anti-psychotic medication |
Key exclusion criteria | 1. Patients who do not speak English or cannot use an interpreter because this will be another confounder to the study 2. Patients with drug dependency as indicated by the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)although alcohol/drug abusers will still be eligible for the study. The DSM- IV criterion for abuse is very restrictive and would capture most alcohol/drug use by mental health service users. The CPNs will be provided with this to make this assessment 3. Organic brain diseases (e.g. dementia) as assessed by the psychiatrist. The psychiatrist will be asked to assess whether the patient is capable of giving informed consent and understanding what they have been asked to do 4. Patients who have previously been treated with RP 5. Patients who refuse to provide consent |
Date of first enrolment | 11/09/2006 |
Date of final enrolment | 11/05/2007 |
Locations
Countries of recruitment
- England
- United Kingdom
Study participating centre
Park Royal Centre for Mental Health
London
NW10 7NS
United Kingdom
NW10 7NS
United Kingdom
Sponsor information
Brent Mental Health Service (UK)
Hospital/treatment centre
Hospital/treatment centre
32 London Road
Wembley
Middlesex
HA9 7SS
England
United Kingdom
Funders
Funder type
Hospital/treatment centre
Funded by Brent Mental Health Service and The Brent Relapse Prevention Programme (UK)
No information available
Results and Publications
Intention to publish date | |
---|---|
Individual participant data (IPD) Intention to share | No |
IPD sharing plan summary | Not provided at time of registration |
Publication and dissemination plan | Not provided at time of registration |
IPD sharing plan |
Study outputs
Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
---|---|---|---|---|---|
Results article | results | 01/09/2008 | Yes | No |